Detecting anti–SARS-CoV-2 antibodies in urine samples: A noninvasive and sensitive way to assay COVID-19 immune conversion

Serum-based ELISA (enzyme-linked immunosorbent assay) has been widely used to detect anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. However, to date, no study has investigated patient urine as a biological sample to detect SARS-CoV-2 virus-specific antibodies. An in-ho...

Descripción completa

Detalles Bibliográficos
Autores principales: Ludolf, Fernanda, Ramos, Fernanda F., Bagno, Flávia F., Oliveira-da-Silva, João A., Reis, Thiago A. R., Christodoulides, Myron, Vassallo, Paula F., Ravetti, Cecilia G., Nobre, Vandack, da Fonseca, Flavio G., Coelho, Eduardo A. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106288/
https://www.ncbi.nlm.nih.gov/pubmed/35559681
http://dx.doi.org/10.1126/sciadv.abn7424
Descripción
Sumario:Serum-based ELISA (enzyme-linked immunosorbent assay) has been widely used to detect anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. However, to date, no study has investigated patient urine as a biological sample to detect SARS-CoV-2 virus-specific antibodies. An in-house urine-based ELISA was developed using recombinant SARS-CoV-2 nucleocapsid protein. The presence of SARS-CoV-2 antibodies in urine was established, with 94% sensitivity and 100% specificity for the detection of anti–SARS-CoV-2 antibodies with the urine-based ELISA and 88% sensitivity and 100% specificity with a paired serum-based ELISA. The urine-based ELISA that detects anti–SARS-CoV-2 antibodies is a noninvasive method with potential application as a facile COVID-19 immunodiagnostic platform, which can be used to report the extent of exposure at the population level and/or to assess the risk of infection at the individual level.

Ejemplares similares